08.08.25 -- 5 Cs For Responding To FDA-483s — Strategies For Effective Compliance And Resolution

This is Part 1 of a 3-part series demonstrating how robust data analytics can address the real-world implications of data quality issues that affect patients waiting for effective treatments.

Uncover how Phase 4 trials play an essential role in gathering additional real-world data on the treatment’s performance over a longer period of time and in more diverse patient populations.

Building an "analytics culture" in clinical research requires striking a balance between fast, flexible technologies and the right support for trial teams working to integrate these solutions.

Learn about Medical Information (MI) Services that deliver innovative, AI-driven, and globally scalable solutions to meet the evolving needs of pharmaceutical companies.

In this presentation, the panel of experts focuses on the changes AI has brought to cardiac monitoring data during clinical trials and addresses the skepticism over the use of new innovations.